As I understand it, the company have been focussing on growth in the US, and will more than likely turn that focus to the rest of the world once their objectives have been met in the US. FDA approval, and the ability to sell in the US, is a massive incentive for the rest of the world to take notice of this company and the products they have. Great update, and for my money, the CR price will be a distant memory in the not too distant future.
Ann: EYE February sales update, page-6
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.010(4.35%) |
Mkt cap ! $50.34M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 22.0¢ | $170.5K | 753.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 264524 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 63154 | 2 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
22.0¢ |
Change
-0.010 ( 6.38 %) |
||||
| Open | High | Low | Volume | ||
| 23.0¢ | 23.5¢ | 22.0¢ | 293179 | ||
| Last updated 15.58pm 07/06/2024 ? | |||||
| EYE (ASX) Chart |